Amgen (NASDAQ:AMGN) Given New $410.00 Price Target at Daiwa Securities Group

Amgen (NASDAQ:AMGN) had its price target raised by Daiwa Securities Group from $370.00 to $410.00 in a research report sent to investors on Tuesday,MarketScreener reports. Daiwa Securities Group currently has an outperform rating on the medical research company’s stock.

Several other equities analysts have also recently weighed in on the stock. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Wall Street Zen cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Saturday. Scotiabank initiated coverage on shares of Amgen in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target on the stock. Morgan Stanley upped their price objective on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Wells Fargo & Company raised their target price on Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $353.39.

Amgen Price Performance

NASDAQ AMGN opened at $364.65 on Tuesday. The business’s fifty day moving average price is $335.74 and its 200-day moving average price is $312.39. The stock has a market capitalization of $196.36 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 3.85 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen has a 1-year low of $261.43 and a 1-year high of $385.12.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the company posted $5.31 earnings per share. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts predict that Amgen will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is presently 66.90%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the fourth quarter valued at about $26,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the second quarter worth about $27,000. Finally, Evelyn Partners Investment Management LLP purchased a new stake in shares of Amgen in the second quarter worth about $32,000. 76.50% of the stock is currently owned by institutional investors.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.